{
    "2021-04-30": [
        [
            {
                "time": "2021-04-30",
                "original_text": "A股主力资金流向（4月30日）：医药股获资金爆买",
                "features": {
                    "keywords": [
                        "A股",
                        "主力资金",
                        "医药股",
                        "资金流向"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-Q1",
                "original_text": "东莞证券维持华熙生物推荐评级，2021年一季报点评：功能性护肤品持续高增长，功能性食品强劲起势",
                "features": {
                    "keywords": [
                        "华熙生物",
                        "一季报",
                        "功能性护肤",
                        "功能性食品",
                        "高增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "化妆品"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-Q1",
                "original_text": "东方财富证券维持华熙生物增持评级，2021年一季报点评，近期获32份券商研报关注，目标均价跌幅14.15%",
                "features": {
                    "keywords": [
                        "华熙生物",
                        "一季报",
                        "券商研报",
                        "目标均价跌幅"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "化妆品"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-Q1",
                "original_text": "东吴证券维持华熙生物买入评级：营收+111%，化妆品业务高速增长，医美业务提速可期，玻尿酸龙头壁垒高筑",
                "features": {
                    "keywords": [
                        "华熙生物",
                        "买入评级",
                        "营收增长",
                        "化妆品",
                        "医美",
                        "玻尿酸"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "化妆品"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-Q1",
                "original_text": "大股东清仓式减持一周套现30亿，医美股不香了？减持股份",
                "features": {
                    "keywords": [
                        "大股东",
                        "减持",
                        "医美股",
                        "套现"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医美"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-Q1",
                "original_text": "明星私募一季度调仓：冯柳现身25家公司持仓超300亿，高瓴礼仁新进安图生物、伊利",
                "features": {
                    "keywords": [
                        "明星私募",
                        "冯柳",
                        "高瓴礼仁",
                        "安图生物",
                        "伊利"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-Q1",
                "original_text": "多位明星基金经理增持，医药板块上涨的空间还大吗?丨牛熊眼",
                "features": {
                    "keywords": [
                        "明星基金经理",
                        "增持",
                        "医药板块",
                        "上涨空间"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}